Sarcomas | Specialty

Use of Targeted Therapy in GIST Mutations

March 25th 2020

Targeted Therapy Advancements in Sarcoma Subtypes

March 25th 2020

Soft Tissue Sarcoma: Unmet Needs

March 25th 2020

The Prognostic Value of Molecular Testing

March 25th 2020

Switching Therapy: Secondary Mutations and Resistance

March 25th 2020

Current Treatment Landscape of Soft Tissue Sarcoma

March 25th 2020

Diagnostic Testing Procedure for Soft Tissue Sarcoma

March 25th 2020

NY-ESO-1, MAGE-A4 Among Key Targets in Sarcoma Research

March 17th 2020

Neeta Somaiah, MD, discusses ongoing research in the field of sarcoma.

Key Advances in Sarcoma Lead to More Personalized Medicine Efforts

March 17th 2020

Jonathan C. Trent, MD, PhD, discusses recent advances and ongoing research in the field of soft tissue sarcoma.

Avapritinib Is a Game Changer for PDGFRA Exon 18-Mutated GIST

March 14th 2020

Michael C. Heinrich, MD, discusses the recent approval of avapritinib for advanced PDGFRA exon 18–mutated gastrointestinal stromal tumor.

Deeper Understanding of Osteosarcoma Biology Explains Challenges With Immunotherapy

March 5th 2020

Multiple immune-infiltrate features in the immune-genomic landscape of osteosarcoma, such as poor tumor infiltration by immune cells, low T-cell activity, a lack of immune-stimulating neoantigens, and immune-suppressing pathways, contribute to the limited clinical activity associated with checkpoint inhibitors in this disease, according to results of a study published in Nature Communications.

Dr. Lazarides on Research Regarding Margin Assessment in Sarcoma

February 28th 2020

Alexander Leandros Lazarides, MD, discusses research regarding margin assessment in patients with sarcoma.

Dr. Gibbs on the Lack of Treatment Options in Sarcoma

February 27th 2020

C. Parker Gibbs Jr, MD, discusses the lack of treatment options for patients with soft tissue and bone sarcomas.

CRM1 Emerges as a Potential Target in Osteosarcoma in Novel Drug Discovery Model

February 26th 2020

Alexander Leandros Lazarides, MD, discusses the need for better drug discovery models in osteosarcoma and provides insight into a new personalized medicine pipeline that has the potential to redefine drug development in the field.

Randall Ruminates on Challenges With Treating Sarcomas in AYA Patients

February 25th 2020

R. Lor Randall, MD, FACS, highlights the specific challenges faced by adolescent and young adult patients with sarcomas, the importance of promoting awareness of this issue, and the resources available to improve outcomes in this population.

Musculoskeletal Tumor Registry Collects QoL Data After Surgery in Sarcoma

February 21st 2020

Benjamin J. Miller, MD, MS, discusses the creation of the Musculoskeletal Tumor Registry and how it is poised to make progress in the orthopedic oncology field.

Dr. Randall on the SAFETY Trial in Soft Tissue Sarcoma

February 14th 2020

R. Lor Randall, MD, FACS, discusses the SAFETY trial (NCT03944798) in soft tissue sarcoma.

Dr. Eward on the Unmet Need for Novel Agents for TGCT and Sarcoma

February 14th 2020

William Eward, MD, DVM, discusses the unmet need for novel agents in tenosynovial giant cell tumor and sarcoma.

Pathological Fractures Linked to Inferior OS in Adults With Osteosarcoma

February 12th 2020

Pathological fractures in adult patients with high-grade osteosarcoma of the extremities potentially correlates with inferior overall survival.

Dr. Lawrenz on Patient Feedback of Preoperative 5-Fraction RT Sarcoma Study

February 4th 2020

Joshua M. Lawrenz, MD, discusses patient feedback of a study on preoperative 5-fraction radiation therapy for soft tissue sarcoma with immediate resection.